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Synthetic cannabinoids (SCs) represented 45% of the new psychoactive substances seizures 
in Europe (data from 2016). The consumption of SCs is an issue of concern due to the still 
unknown toxicity and effects on human health, the great variety of compounds synthetized and 
continuous modifications in their chemical structure to avoid regulatory issues. These 
compounds are extensively metabolised in the organism and therefore often cannot be detected 
as the intact molecule in human urine. For this reason, the monitoring of SCs in forensic 
samples must be performed by the analysis of its metabolites. In this work, a workflow for the 
comprehensive study of SC consumption is proposed and applied to 5F-APP-PICA (also 
known as PX 1 or SRF-30) and AMB-FUBINACA (also known as FUB-AMB or MMB-
FUBINACA), based not only on the elucidation of their metabolites but also including 
functional data. Both cannabinoids were completely metabolised by human hepatocytes (12 
and 8 metabolites were elucidated by high resolution mass spectrometry for 5F-APP-PICA and 
AMB-FUBINACA, respectively) and therefore suitable consumption markers have been 
proposed. The bioassays revealed that 5F-APP-PICA presented lower activity than AMB-
FUBINACA at CB1 and CB2 receptors. These results are in agreement with the different 
intoxication cases found in literature for AMB-FUBINACA. 
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1. Introduction  
Synthetic cannabinoids (SCs) are among the most frequently seized new psychoactive 
substances (NPS), according to the 2018 European Monitoring Centre for Drug and Drug 
Addiction (EMCDDA) report [1]. In 2016, SCs represented 45% of the NPS seizures in Europe, 
being the largest NPS group monitored by the EMCDDA (179 compounds) [1]. Although these 
compounds can be found as faux hash and e-liquids for vaping [2], they are typically sold on 
webpages or in smartshops [3–5] as “herbal blends” or “spice”, and used as cannabis substitution. 
In the last years, SCs are also being found as powder [1]. In 2017, 10 new SCs were detected 
for the first time in Europe [1], illustrating the continuous emergence of this type of substances 
[1,6]. The constant modifications in the chemical structure of these compounds constitute an 
analytical challenge for forensic laboratories, which must apply state-of-the-art techniques for 
compound identification, such as high-resolution mass spectrometry (HRMS) or nuclear 
magnetic resonance (NMR) [7–9], in most cases without having reference standards available 
for their rapid confirmation. 
It is known that several SCs present more intense psychoactive and side effects than THC, 
given their full agonism at the cannabinoid receptors CB1 and CB2, while THC only partially 
activates these [10,11]. The fact that SCs possess higher potency at the CB1 and CB2 could also 
increase the health risk for drug consumers, as reported in several overdose cases [12–18]. 
Nevertheless, it has not been confirmed yet that toxicity of SCs is strictly a function of potency 
and/or efficacy. 
As most of the drug tests performed for the treatment of cannabis dependence are based on 
the detection of THC-COOH (the main urinary metabolite of THC), SCs can be used to by-
pass urine controls [19]. Monitoring SC consumption is very important, for example in 
intoxication cases in hospitals or psychiatric centres. Such control cannot be performed by 
targeted methodologies directed towards the parent compounds, as these are rapidly 
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metabolised in the liver, resulting in little or no unaltered compound in urine [20]. This forces 
analytical laboratories to develop methodologies focused on the major urinary metabolites 
[21,22], which constitutes an additional challenge for detecting the use of SCs. Ideally, in order 
to stablish the best consumption biomarkers, urine samples from SC consumers [23–26] should 
be collected to study their metabolism. However, the availability of this type of samples is 
mostly limited to medical emergency cases. To circumvent this problem, different strategies 
can be used. In the in vivo approach, healthy animals (typically mice[27] or rats[28–30]) are 
exposed to the compound of interest, and blood and urine samples are usually collected in order 
to elucidate the metabolites. Nevertheless, it is possible that some metabolites obtained with an 
animal model are not found in humans, or the major metabolites identified in humans are not 
the major ones in other species. As an alternative, in vitro approaches using human liver 
microsomes [31], S9 fractions or hepatocytes [31], have produced reliable human excretory 
metabolites when studying pharmaceuticals. Human liver microsomes [26,32] or hepatocytes 
[24,33,34] have already been used for the metabolism study of new synthetic drugs such as SCs. 
Confirmation of these in vitro metabolites via the analysis of authentic samples (especially 
urine) has proven the suitability of the different in vitro strategies to predict human metabolic 
products [24,32]. 
As important as the determination of the most suitable consumption biomarkers of SCs is 
the evaluation of their potency and/or affinity at CB1 and CB2 receptors [35–37], which reveals 
another important aspect of these drugs and brings new insights on their pharmacology. To this 
aim, different bioassays have been used for both SCs as well as their metabolites and 
degradation products. 
In order to obtain a complete overview on the problem of SC consumption, a three-step 
strategy has been used in this work: i) Metabolism study for establishing the metabolic pathway 
and the most suitable consumption biomarkers. ii) Detectability and/or stability of the parent 
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compound and its metabolites during incubation, which could be extrapolated to the excretion 
through urine in intoxication cases. iii) Estimation of their potency using activity-based CB1 
and CB2 receptor bioassays. The proposed strategy has been applied to the 1-pentyl-1H-
indazole-3-carboxamide derivative 5F-APP-PICA (also known as PX 1 or SRF-30), and the 
(4-fluorophenyl)methyl-1H-indazole-3-carboxamide derivative AMB-FUBINACA (also 
known as FUB-AMB or MMB-FUBINACA), which are amongst the most common SCs seized 
in powder and smoking mixtures in Spain and Europe [38], respectively. Several phase I and 
phase II metabolites have been identified thanks to the use of accurate-mass data provided by 





2.1. Reagents and chemicals  
5F-APP-PICA and AMB-FUBINACA were kindly provided by Energy Control 
(Asociación Bienestar y Desarrollo, Barcelona, Spain). Compound purity was tested by 
nuclear magnetic resonance. 5F-Py-PICA (internal standard, IS) was kindly provided by the 
Slovenian National Forensic Laboratory.  
For hepatocyte incubation, diclofenac was purchased from Sigma-Aldrich (St. Louis, MO, 
USA). Trypan blue solution (0.4%), fetal bovine serum (FBS), Leibovitz’s L-15 medium, 
Gibco cryopreserved hepatocyte recovery medium, methanol, acetonitrile, ultrapure water, 
Pierce® LTQ Velos ESI positive Ion calibration solution, PierceTM ESI negative ion 
calibration solution, and formic acid (LC‒MS grade) were obtained from Fisher Scientific 
(Leicestershire, UK). The pooled human hepatocytes (pHH) from a pool of 10 were 
purchased from Lonza (Basel, Switzerland), and stored in liquid nitrogen until use. 
For cannabinoid receptor bioassays, JWH‐018 was purchased from LGC (Wesel, 
Germany). Poly‐D‐lysine and fetal bovine serum (FBS) were from Sigma‐Aldrich 
(Steinheim, Germany). Opti‐MEM I Reduced Serum, Dulbecco's modified eagle medium 
(DMEM), trypsin, penicillin, amphotericin B, streptomycin, and glutamine were supplied by 
Thermo Fisher Scientific (Pittsburg, PA, USA). Nano‐Glo® Live Cell substrate furimazine 
and Nano‐Glo® dilution buffer were purchased from Promega (Madison, WI, USA). 
Methanol and DMSO were purchased from Fisher Scientific. 
2.2. Pooled human hepatocyte incubation 
Incubation with pooled human hepatocytes was performed at 10 μM of each SC during 180 
min, with collection of aliquots at 0, 60 and 180 min. Briefly, cryopreserved pooled human 
hepatocytes were rapidly thawed in a water bath at 37 °C, mixed with 50 mL preheated 
recovery medium, and centrifuged at 168 g for 20 min to remove dead hepatocytes. After 
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aspiration of the supernatant, the hepatocytes were washed by resuspending the pellet in 20 mL 
growth medium (L-15 with 10% FBS), and centrifuging for 5 min at 50 g. Then, the supernatant 
was aspirated and the resulting pellet was re-suspended in growth medium for cell counting by 
the trypan blue exclusion method. The measured viability was 71%. The hepatocyte suspension 
was diluted to 106 viable hepatocytes/mL incubation medium. 5F-APP-PICA, AMB-
FUBINACA, or diclofenac (positive control) were added at a final concentration of 10 
μM; the maximum organic content of the incubation was 0.3%. The incubations were 
performed in duplicate for each condition in 96-well plates, at 350 rpm and 37 °C, on a 
Thermomixer comfort (Eppendorf, Hamburg, Germany). Controls without the addition of 
hepatocytes were run simultaneously to identify hydrolysis products and artefacts. 
Aliquots of 20 μL were collected after 0 (with a latency between 2-3 min), 60, and 180 
min of incubation and mixed with 80 μL of an ice-cold acetonitrile solution containing 
100 ng/mL of IS. The extracts were frozen until analysis. 
2.3. Instrumentation 
Extracts were analyzed using a Dionex Ultimate 3000 UHPLC system from Thermo 
Scientific (Germering, Germany) coupled to a Q Exactive high resolution mass spectrometer 
from Thermo Scientific (Bremen, Germany) equipped with a hybrid quadrupole-Orbitrap 
mass analyzer.  
Chromatographic separation was performed using an Acquity HSS C18 1.8 μm, 2.1×150 
mm column from Waters (Wexford, Ireland), which was maintained at 40 °C. The mobile 
phase consisted of 5 mM ammonium formiate buffer with 0.1% v/v formic acid (solvent A) 
and 0.1% v/v formic acid in acetonitrile (solvent B), which was delivered at a flow rate of 
0.25 mL/min. A 14 min gradient was used for the identification of metabolites, starting at 
5% B (0‒0.5 min), increasing to 99% B (0.5–10 min), where it remained isocratic for 2 min 
and followed by re-equilibration for 2 min. The autosampler temperature was 5 °C. The 
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injection volume was 3 μL. 
UHPLC was coupled to the HRMS using a heated electrospray ionization source (HESI-
II) (Thermo Scientific, Bremen, Germany) working in positive (ESI+) and negative (ESI‒) 
ionization modes. The capillary temperature was 350 °C, and the spray voltage was 4.0 kV 
in ESI+ and -4.0 kV in ESI‒. Data were acquired using data-dependent acquisition (dd-MS2, 
DDA) and parallel reaction monitoring (PRM, MS/MS). Full-scan data (FTMS) were 
collected in a scan-range of m/z 200–900 using a resolution of 70,000 FWHM, an automatic 
gain control (AGC) target of 106 ions, a maximum injection time of 50 ms and an isolation 
window of m/z 1. DDA MS/MS was acquired at a resolution of 35,000 FWHM, while PRM 
were acquired at 17,500 FWHM, using an AGC target of 2e5 ions and a maximum IT of 25 
ms. Nitrogen was used as the collision gas at normalized collision energy (NCE) of 10, 30 or 
50 eV.  
The instrument was externally calibrated to a mass accuracy of ±5 ppm using the 
recommended calibration solutions for this instrument (Pierce® LTQ Velos ESI positive Ion 
calibration solution, PierceTM ESI negative ion calibration solution, Thermo Scientific), 
purchased from Thermo Scientific. The instrument was controlled by XCalibur 4.0 software 
(Thermo Scientific, MA, Waltham, USA). Data processing was performed using Compound 
Discoverer 2.0 software (Thermo Scientific) for a preliminary compound identification, and 
FreeStyle 1.3 (Thermo Scientific) for working with raw data. 
2.4. Cannabinoid receptor bioassays  
The potency and efficacy (the latter relative to JWH-018, used here as a reference) were 
estimated via the calculation of the half maximal effective concentration (EC50) and the 
maximum response (Emax), respectively. Both parameters were determined using live cell-
based reporter assays based on the application of the NanoLuc Binary Technology, that 
evaluates the interaction between the cytosolic protein β-arrestin 2 (βarr2) to CB1 and CB2 
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expressed in human embryonic kidney (HEK) 293T cells. Details regarding the development 
of the stable CB1 and CB2 cell lines used here and the experimental conditions have been 
reported elsewhere [39,40]. In brief, cells were seeded on a poly-D-lysine-coated 96-well plate at 
5×104 cells/well and incubated overnight at 37°C and 5% CO2. Following 24 h, the cells were 
washed twice with 150 µL Opti-MEM I Reduced Serum and finally 100 µL of Opti-MEM I 
was added to each well. The Nano-Glo® Live Cell Reagent (Promega), a nonlytic detection 
reagent containing the live cell permeable furimazine substrate, was prepared by diluting the 
substrate 20× in Nano-Glo® LCS dilution buffer, and 25 µL was added to each well. The plate 
was placed in a luminometer and after stabilization of the signal (~20 min), 10 µL of 13.5× 
stock solutions (concentration range: 0.01–10 µM) of the 5F-APP-PICA or AMB-FUBINACA 
in 50% methanol in Opti-MEM I was added and the luminescence was continuously measured 
for 2 h (n=5-7). Replicates of solvent (50% methanol in Opti-MEM I) were run in all 
experiments as negative controls and were used to correct the signal. The final concentration 
of methanol (3.7%) did not pose a problem given the advantage of the short readout time of the 
assay. 
Curve fitting of concentration-effect curves via nonlinear regression (four parameter logistic 
fit) was employed to determine EC50 (measure of potency) and Emax values (measure of 
efficacy). The Emax values are normalized to the Emax value of JWH-018 (100%), used as a 
reference in our study, and hence are a ‘relative measure’ of efficacy.  
3. Results and discussion 
3.1. Fragmentation of the synthetic cannabinoids 
It is expected that parent compounds and metabolites present very similar fragmentation 
pathways. So, an accurate study of the MS fragmentation of the parent compound is extremely 
useful for metabolite elucidation. The presence of common fragments between parent and 
metabolite indicates that the biotransformation has not occurred in this part of the molecule. 
11 
 
The remaining fragments observed for metabolites usually present a mass shift when compared 
to the corresponding fragments of the parent compound, commonly corresponding to the 
biotransformation. So the identification of these mass fragments is crucial to correctly locate 
the position in which the biotransformation has occurred. This methodology has been 
successfully used for NPS metabolite identification[41,42]. Nevertheless, it has to be taken into 
account that some biotransformations can affect the whole fragmentation pathway of the 
metabolite, which may become very different from the parent.  
Figure SI1 (in Electronic Supplementary Information) shows the MS/MS spectra of 5F-
APP-PICA (C23H27FN3O2
+, m/z 396.2083, 0.18 ppm) at 10 eV (top) and 50 eV (bottom) 
collision energy. Table SI1 lists its fragments, including accurate mass, elemental composition 
and mass error. The terminal amide moiety easily breaks similarly to ADB-PINACA, 5F-AB-
PICA and AB-FUBINACA, producing the loss of an ammonia molecule (Fragment 1, 
C23H24FN2O2
+, m/z 379.1815, -0.38 ppm). The Fragment 2 (C14H15FNO
+, m/z 232.1132, -0.39 
ppm) would correspond to the disconnection of the peptide bond of the amide moiety linked to 
the indole ring. This fragmentation is also observed for ADB-PINACA, 5F-AB-PICA and AB-
FUBINACA (which have an indazole group instead of indole) and, APICA and SDB-006 
(indole ring). Fragment 2 could also come from the protonated molecule ([M+H]+) when the 
protonation is produced in the amide moiety linked to the indole ring. Finally, this fragment 
ion at m/z 232, consisting of the indole ring with the N-alkyl moiety and the carbonyl moiety, 
indicates an N-dealkylation and consequent release of the indazole with the carbonyl moiety 
(Fragment 3, C9H6NO
+, m/z 144.0444, -0.02 ppm). This N-dealkylation has also been reported 
for AB-FUBINACA and ADB-PINACA. Nevertheless, the cyclopentylium ion (Fragment 4, 
C5H9
+, m/z 69.0706, 11.17 ppm) has not been observed for related compounds when a QTOF 
instrument is used [6]. This could be consequence of the different geometry of the collision cell 
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used in both instruments. Figure SI3 shows the proposed fragmentation pathway for 5F-APP-
PICA, once evaluated the observed fragmentation. 
Figure SI2 and Table SI2 show the mass spectrometric behaviour of AMB-FUBINACA 
(C21H23FN3O3
+, m/z 384.1717, -0.35 ppm) at 10 eV (top) and 30 eV (bottom). The first 
fragment corresponds to the ester bond disconnection and subsequent loss of methanol 
(Fragment 1, C20H19FN3O2
+, m/z 352.1455, -0.12 ppm), equivalent to the ammonia loss 
observed for 5F-APP-PICA. Subsequently, a CO loss is produced (Fragment 2, C19H19FN3O
+, 
m/z 324.1507, 0.09 ppm). After that, the peptide bond is disconnected, releasing the indazole 
ring bonded to the carbonyl moiety (Fragment 4, C15H10FN2O
+, m/z 253.0771, -0.14 ppm). 
Peptide bond can also be disconnected from the [M+H]+ protonated in the amide moiety, as 
explained in Figure SI4. This behaviour has also been reported for ADB-FUBINACA and AB-
FUBINACA [26,43]. Finally, an N-dealkylation is produced, resulting in a fluorotropylium ion 
(Fragment 5, C7H6F
+, m/z 109.0451, 3.45 ppm), also reported for cannabinoids with a 
fluorobenzyl moiety [26,43]. Similarly to Fragment 4, the fluorotropylium fragment ion could be 
produced directly from the protonated molecule after an N-alkyl disconnection (Figure SI4). 
An additional fragment is observed at m/z 271.0877 (Fragment 3, C15H12FN2O2
+, -0.09 ppm), 
obtained after the addition of a water molecule to Fragment 4. The generation of adducts 
between unstable ions and neutral molecules, specially water molecules, has been previously 
reported for Q-Orbitrap instruments [44]. As stated by those authors, these adducts are less 
promoted in QTOF instruments, due to the different geometry of the collision cell.  
Although there are differences in the fragmentation of both compounds, a generic 
fragmentation pathway can be proposed based on most of the observed ions (see Figure 1). 
The information about the fragmentation pathway of both synthetic cannabinoids can be used 
by forensic laboratories for the identification of these SCs, but also for elucidation of similar 
cannabinoids, as most present similar fragmentation [6,43–45].  
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Tables SI1 and SI2 show the fragmentation observed for all the 5F-APP-PICA and AMB-
FUBINACA metabolites, respectively,  in ESI+ and ESI‒, including the chromatographic 
retention time, and the elemental composition and mass error of the (de)protonated molecule 
and its fragments.  
3.2. Analytical strategy for metabolite identification 
Once samples were injected into the UHPLC-HRMS system using data dependent 
acquisition mode (DDA), Compound Discoverer 2.0 software was used for data processing. A 
list of expected metabolites was obtained based on presumed biotransformations. The software 
automatically performed extracted ion chromatograms (EIC) (with a mass window of ±5 ppm) 
for the (de)protonated molecule of the expected metabolites. Compounds that were present in 
incubation samples but not in blanks nor stability samples were considered as potential 
metabolites.  
MS/MS spectra of the potential metabolites, acquired during DDA, were studied using 
FreeStyle 1.3 software. Those potential metabolites that presented a plausible fragmentation 
(i.e. the MS/MS spectra fit with the expected biotransformation) were considered for a re-
analysis by UHPLC-HRMS using parallel reaction monitoring acquisition (PRM) at three 
different collision energies (10, 30 and 50 eV). If not, they were directly discarded. 
Based on the observed PRM MS/MS fragmentation, the position of the biotransformation 
on the structure was determined. Finally, fragmentation pathways were proposed for all 
metabolites.  
3.3. 5F-APP-PICA metabolites 
The above strategy allowed the identification of 7 phase I metabolites of 5F-APP-PICA. 
Regarding phase II metabolites, 5 compounds were found, all of them corresponding to 
glucuronides (Gluc) of the main phase I metabolites. An exhaustive description on the 
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identification of all metabolites based on the observed fragmentation, including fragmentation 
pathways, can be found in Electronic Supplementary Information. 
Metabolic behaviour  
After elucidating the structures for all metabolites, the metabolic pathway for 5F-APP-PICA 
using human hepatocyte incubation was proposed (Figure 2). As an aliquot of the incubation 
was taken at 0, 60 and 180 min, the prevalence of 5F-APP-PICA and its metabolites in the 
incubation was also studied. Figure 3 shows the relative presence of all the identified 
metabolites, including the parent compound, normalizing all the responses to the one obtained 
for 5F-APP-PICA at 0 min. For metabolites detected in ESI+, 5F-APP-PICA [M+H]+ response 
was used, while metabolites observed in ESI‒ were plotted relative to 5F-APP-PICA [M‒H]‒ 
response. Obviously, an important limitation here is that this approach assumes similar 
ionisation and fragmentation efficiencies for the parent compounds and the metabolites, which 
is not really the case, as can also be deduced from the fact that the sum of the obtained % 
(strongly) deviates from 100%. Still, this approach allows to get an idea about the appearance 
and further conversion of metabolites. 
Metabolic biotransformations seem to be focused on the removal of heteroatoms from both 
sides of the molecule. One of the most abundant biotransformations at 0 min was the oxidative 
defluorination (M1), together with the oxidation of the hydroxyl group in the alkylic chain after 
oxidative defluorination (M2). These two biotransformations have been reported for other 
synthetic cannabinoids with an N-fluoropentyl moiety, such as MAM-2201 [45], 5F-AB-
PINACA [46] and 5F-AMB [47]. The other most abundant biotransformation at 0 min, the 
oxidative deamination (M3), has also been widely reported in literature for synthetic 
cannabinoids with terminal amide moieties, such as AB-FUBINACA [24], AB-PINACA [46] and 
5F-AB-PINACA [46]. As expected, combinations of these biotransformations were also found 
(M4 and M5). The N-dealkylation of the fluoropentyl moiety (M6) has also been reported for 
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MAM-2201 [45]. Similarly to M4 and M5, the metabolite M7 was obtained after oxidative 
deamination from M6. Additional biotransformations described for these cannabinoids, such 
as N-alkyl hydroxylation/oxidation, were not found for 5F-APP-PICA [45,47]. 
5F-APP-PICA was rapidly metabolised during incubation. At 60 min, only 20% of the initial 
response was present, with less than 0.5% remaining at 180 min, as depicted in Figure 3. M1 
presented an important response at 0 min, but it started to decrease at 60 min. It is possible that 
the increment in the relative response of M2 after 60 min is related to the decrease of M1 at the 
same time, as M1 is transformed to M2, and also to M4. M2-M5 presented a continuous 
increase in response over time, with especially M5 increasing substantially after the 60 min 
time point. M6 presented a relative concentration of 11% at 0 min, while M7, which is derived 
from M6, was present at 10% at 180 min, with an increase in M7 being accompanied by a 
decrease in M6. Finally, glucuronide conjugates were not significantly important, all being 
below 3% of relative response. The most abundant phase II metabolite was M5-Gluc (2.85%), 
as expected after evaluation of phase I metabolites. 
Based on these results, M3, M4 and M5 were the most abundant metabolites at 180 min, and 
thus could be selected as potential biomarkers for the determination of 5F-APP-PICA 
consumption in forensic samples. We are not aware of authentic cases that have been reported 
in literature via which these biomarkers could be validated. 
3.4. AMB-FUBINACA metabolites 
Six phase I metabolites and one phase II metabolite, corresponding to the glucuronide 
conjugate of the main phase I metabolite, were identified for AMB-FUBINACA. All the 
identified metabolites were detected in ESI+. The fragmentation study performed for the 




Once all the AMB-FUBINACA metabolites were identified, the metabolic pathway for this 
SC was proposed (Figure 4). Similarly to 5F-APP-PICA, the prevalence of AMB-FUBINACA 
and its metabolites was studied, normalizing all the responses to the response obtained for the 
parent compound at 0 min (Figure 5). Also here, a limitation is that similar ionization and 
fragmentation efficiencies are assumed for the main compound and its metabolites. 
Metabolic biotransformations were focused on the increment of polarity of the compound, 
by dealkylations and hydroxylations. The most abundant metabolite was M1, produced after 
O-demethylation of AMB-FUBINACA. The slight increase in relative response of M1 after 60 
min could be owing to small variations in the response of the instrument. The O-dealkylation 
has already been reported for other SCs with terminal ester moieties, such as MDMB-CHMICA 
[32]. M1 seems to be the precursor compound for the phase I hydroxylated metabolites M2-4. 
The hydroxylation after an O-demethylation has been described in literature, but only in the 
alkyl moiety (isopropyl for AMB-FUBINACA, and isobutyl for MDMB-CHMICA[32]) 
positioned between the amide and ester groups. For AMB-FUBINACA, three different 
positions for hydroxylation could be deduced, based on the observed fragmentation: 
hydroxylation in each one of the methyl groups (M3) and in the tertiary carbon (M2) of the 
isopropyl group; for MDMB-CHMICA, instead, the position of the hydroxyl group could not 
be established unequivocally by the authors [32]. In the case of M4, the hydroxylation took place 
on the indazole ring. M5 is the result of an indazole hydroxylation directly from the parent 
compound. So, M5 could also be metabolized into M2 following an O-demethylation process. 
Regarding M6, this metabolite was produced after N-dealkylation of M1. This 
biotransformation has been observed for SCs with an indazole ring and an N-fluorobenzyl 
moiety, such as ADB-FUBINACA and AB-FUBINACA[26,43]. Finally, an additional potential 
metabolite was obtained after N-methylation of M6 (M6-Methyl), as either an enzymatic 
reaction or artefact formation. No information about the N-methylation of related drugs has 
17 
 
been found. N-methylation of amines are common artefacts when working with methanolic 
solutions [48], particularly at elevated temperatures. In the present study, the compounds were 
dissolved in methanol and later incubated at a low final methanolic concentration level of 0.3%. 
The quenching solution and mobile phases were acetonitril-based which should not form N-
methyl artefacts. In order to determine whether M6-Methyl is an artefact or a metabolite, the 
experiment should be repeated using CD3OH as dissolving agent to observe if there is a 
corresponding accurate mass shift. Additional biotransformations described for other imidazole 
cannabinoids, such as amide N-dealkylation or polyhydroxylation, were not found for AMB-
FUBINACA [26,43]. 
AMB-FUBINACA was metabolised extremely fast. At 0 min, M1 represented near 1900% 
of parent response, illustrating that the O-demethylation is the most important and rapid 
biotransformation. O-demethylated metabolite represented less than 1% in the biological blank 
(incubation without hepatocytes), indicating that this metabolite is not an impurity from the 
compound or a degradation product. Two hypothesis could explain the huge relative response 
observed for M1 at 0 min. One reason could be related to the little delay (2-3 min) between the 
incubation starting and the aliquot collection times, which could be enough for the O-
demethylation reaction occurring. The second one could be the much higher efficient ionisation 
of M1 respect to parent compound. At 60 min, only 0.5% of AMB-FUBINACA remained, as 
can be observed in Figure 5. M1-Gluc increased over time, until 16% at 180 min, as expected, 
given the fact that M1 is the most important compound present in the incubation mixture. The 
other metabolites (M2-M5) were below 1% at 180 min, and only M6 (1.6% at 180 min) and 
M6-Methyl (7.2% at 180 min) yielded a noteworthy response in the incubations. It could be 
possible that other reactions might be more prominent but the resulting metabolites might not 
give a good MS response. Therefore, based on MS response, M1 would be the most suitable 
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metabolite to be considered as a biomarker for the determination of AMB-FUBINACA 
consumption in real samples.  
In a recent report where AMB-FUBINACA was associated with a massive intoxication [49], 
the parent compound was not detected in blood while the carboxylic metabolite was detected 
at high concentrations in the urine samples. Also Staeheli and colleagues reported on the 
detection of the M1 metabolite in urine of a SC user, although these authors did find some 
remaining AMB-FUBINACA main compound in urine as well [50]. Overall, these data are in 
agreement with the results obtained in this article, showing the usefulness of our in vitro 
studies.  
3.5. Potency and efficacy of synthetic cannabinoids 
The EC50 and Emax values were estimated for 5F-APP-PICA and AMB-FUBINACA. The EC50 
value of 5F-APP-PICA at CB1 could not be estimated as it did not reach a plateau within the 
tested concentration range, however a maximal effect of 88.9% (relative to JWH-018) at 10 
µM was attained, indicating that even very high concentrations of 5F-APP-PICA only result in 
a partial recruitment of βarr2 to CB1. This weak activity of 5F-APP-PICA at CB1 might be the 
reason why this SC has not been associated with overdose cases so far. However, the 
correlation between the signalling pathway (in our case: βarr2 recruitment to the receptor, 
induced by the agonist) and the effects observed in humans after intake has not been fully 
elucidated for any of both receptors [51]. On the other hand, 5F-APP-PICA did show activity at 
CB2, with an EC50 of 83.2 nM and showing an Emax similar to that observed for the control 
JWH-018 (i.e. 96.6% of the JWH-018 Emax) (Table 1). To the best of the authors’ knowledge, 
there are no reference concentrations of 5F-APP-PICA in blood, so it is not possible to 
extrapolate our EC50 value to an in vivo situation.  
With EC50 values of 9.84 nM and 2.40 nM for CB1 and CB2, respectively, AMB-
FUBINACA was much more potent than the control JWH-018 at both receptors, for which 
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EC50 values of 41.0 and 12.3 were obtained 
[40]. Interestingly, also the Emax values for this SC 
are substantially higher than that observed for JWH-018, especially at CB1 (approximately 2.5 
fold). Therefore, AMB-FUBINACA is not only more potent, but it also generates a stronger 
response at CB1 than the reference compound JWH-018 at high concentrations. Although it is 
difficult to compare EC50 values from different assays (due to different experimental setups), 
our low nanomolar values are in line with those found in other reports investigating the in vitro 
an in vivo activity of AMB-FUBINACA [52,53]. More particularly, Banister et al. and Gamage 
et al. estimated the EC50 and the Emax values for AMB-FUBINACA via the FLIPR® assay 
[49] 
and via the [35S]GTP binding assay and via the inhibition of forskolin-stimulated cAMP 
production [50]. Also in vivo data is available for AMB-FUBINACA [54]. All these data indicate 
that AMB-FUBINACA is a potent SC, as also reflected by the reported “Zombie” outbreak 
caused by AMB-FUBINACA in New York in July 2016 [49] and supported by the very high 
potency of the closely related ADB-FUBINACA [54]. Future work should include potency 
testing of the major metabolites, to reveal whether these may contribute to the (toxic) effects 
observed in users. 
 
4. Conclusions 
In this work, a three-step strategy has been proposed for a comprehensive SC in vitro study: 
i) elucidation of the metabolites obtained by pooled human hepatocytes, ii) proposal of 
consumption biomarkers based on the obtained metabolites and their stability during 
incubations, and iii) estimation of the potency and efficacy based on their activation of CB1 
and CB2 receptors.  
This strategy has been applied to two synthetic cannabinoids, 5F-APP-PICA and AMB-
FUBINACA, with a detailed explanation of the experimental procedure, data interpretation and 
compound elucidation. The results obtained revealed that both SCs were extensively 
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metabolised during incubations, explaining why these synthetic drugs may hardly be found in 
urine as unaltered compounds. A total of 7 phase I and 5 phase II metabolites were elucidated 
for 5F-APP-PICA, and 6 phase I and 1 phase I metabolites for AMB-FUBINACA. Three of 
these metabolites are proposed as consumption biomarkers for 5F-APP-PICA, and only 1 
metabolite for AMB-FUBINACA, based on the responses obtained at the end of our in vitro 
incubation studies. The CB bioassays revealed that 5F-APP-PICA does not present a high 
activity at CB receptors (certainly not at CB1), while AMB-FUBINACA shows a high CB1 
activation potential, both in terms of potency and efficacy. The above can be linked to 
intoxication cases reported for AMB-FUBINACA and the absence of cases for 5F-APP-PICA. 
The proposed methodology can be applied to the study of other cannabinoids. The accurate 
and detailed explanation of compound elucidation, based on HRMS data, included in this work 
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Fig. 1 Common fragmentation pathway for 5F-APP-PICA and AMB-FUBINACA. Moieties 













Fig. 3 Prevalence of 5F-APP-PICA and its metabolites in incubation over time. Signals are 






Fig. 4 Proposed metabolic pathway for AMB-FUBINACA, based on the metabolites 






Fig. 5 Prevalence of AMB-FUBINACA and its metabolites in incubation over time. Signals 
are relative to those obtained for AMB-FUBINACA at 0 min 
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Table 1 Half maximal effective concentration (EC50) and efficacy (Emax) of 5F-APP-PICA, 
AMB-FUBINACA and JWH-018 (control) at CB1 and CB2. The range of concentrations 
between brackets indicates the 95% confidence interval (CI). 
 
Compound 
EC50 (95% CI) (nM) Emax (95% CI) (%) 
CB1 CB2 CB1 CB2 
5F-APP-PICA - 83.2 (52.6‒132) - 96.6 (86.1‒107) 
AMB-FUBINACA 9.84 (0.56‒17.3) 2.40 (1.30-4.42) 265 (237‒292) 153 (139‒167) 









3. Results and discussion 
3.3. 5F-APP-PICA metabolites 
Phase I metabolites 
As it has been commented, 7 different phase I metabolites were identified for 5F-APP-PICA. 
The 5 major metabolites (M1-M5) were initially identified in ESI+, and also detected in ESI‒ 
but showing lower sensitivity. The acquisition in ESI‒ allowed the identification of 2 additional 
minor metabolites (M6-M7), not observed in ESI+.  
M1-M5 presented the same fragment at m/z 144 (also present in 5F-APP-PICA, see Table 
SI1), corresponding to the indole ring bonded to the carbonyl moiety (C9H6NO
+). Moreover, 
these metabolites (except M4) presented a fragment at m/z 116 corresponding to the indole ring 
(C8H6N
+). These two fragments evidenced that the indole moiety was not changed during 
hepatocyte incubation, unlike other synthetic cannabinoids for which the hydroxylation of the 
indole moiety has been reported 31,44. Regarding M6 and M7 the fragment ion at m/z 116 
(C8H6N
‒) was also observed, indicating that this moiety remained unaltered. Thus, the 
biotransformations should be placed in the alkylic chain, both amide moieties, and/or the 
aromatic ring bonded to the α carbon atom of amide moieties. 
M1 showed a [M+H]+ at m/z 394.2116 (C23H28N3O3
+, -2.31 ppm), which would correspond 
to an oxidative defluorination. This hypothesis was confirmed after fragmentation evaluation. 
Fragment 2 (m/z 230.1170, C14H16NO2
+, -1.93 ppm) corresponded to the indole ring, with the 
carbonyl moiety and the N-alkylic chain. The corresponding fragment was also present in 5F-
APP-PICA (m/z 232). Moreover, Fragment 5 (m/z 87.0809, C5H11O
+, 5.11 ppm) corresponded 
to the N-alkyl disconnection and release of the 5-hydroxypentanylium ion, confirming the 
position of the hydroxyl group in the alkylic chain. After the dehydration of Fragment 5, 
cyclopentylium ion (m/z 69.0705, C5H9
+, 8.96 ppm) was observed for both M1 and 5F-APP-
PICA. Other observed fragments (see Table SI1) could be justified based on the proposed 
38 
 
structure of M1. MS/MS spectra at 10 and 50 eV for M1, and the proposed fragmentation 
pathway can be found in Figure SI5 and Figure SI6, respectively. 
M2 [M+H]+ was found at m/z 408.1908 (C23H26N3O4
+, -2.42 ppm), and corresponded to the 
oxidation of the hydroxyl group present in the N-alkyl chain of M1. Similarly to M1, fragments 
at m/z 244.0963 (C14H14NO3
+, -1.95 ppm) m/z 101.6000 (C5H9O2
+, 2.66 ppm) established the 
position of the biotransformation to be in the alkylic chain. Fragment 6 (m/z 83.0496, C5H7O
+, 
5.78 ppm) was produced after Fragment 5 dehydration (similarly to M1), while Fragment 7 
(m/z 55.0550, C4H7
+, 14.33 ppm) was produced after a CO loss from Fragment 6. These 
fragmentations can only be justified if there is a carboxylic acid moiety in the N-alkyl chain. 
Additional fragments (see Table SISI1) were justified based on the proposed structure. In 
Figure SI7, MS/MS spectra at 10 and 50 eV can be observed, and Figure SI8 shows the 
proposed fragmentation pathway for M2. 
M3 [M+H]+ was observed at m/z 397.1916 (C23H26FN2O3
+, -2.42 ppm), corresponding to an 
oxidative deamination from 5F-APP-PICA. The four observed fragments were the same 
observed for 5F-APP-PICA (see Table SI1): m/z 232, 144, 116, and 69. Nevertheless, 5F-APP-
PICA, and also M1 and M2, presented the loss of an ammonia molecule which was not 
observed for M3, indicating that the oxidative deamination occurred in the terminal amide 
moiety. Finally, the fragmentation pathway was proposed (Figure SI10) based on the MS/MS 
fragmentation at 10 and 50 eV (Figure SI9). 
M4 presented a [M+H]+ at m/z 395.1958 (C23H27N2O4
+, -1.85 ppm), corresponding to an 
oxidative defluorination plus an oxidative deamination. This metabolite shared some fragments 
with M1 (see Table SI1), concretely at m/z 230, 144, 87, and 69. Only the fragment ion 
corresponding to the indole ring (m/z 116) and the corresponding to the ammonia loss were not 
present in M4. This behaviour indicates that M4 correspond to the oxidative defluorination of 
the N-alkylic chain, followed by oxidative deamination of the terminal amide moiety (or vice 
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versa). In other words, M4 comes from M1 after an oxidative deamination, or from M3 after 
an oxidative defluorination. Once all the fragments were justified based on the structure of the 
metabolite, a plausible fragmentation pathway was proposed (Figure SI12). Additionally, 
MS/MS spectra at 10 and 50 eV can be checked in Figure SI11. 
M5 [M+H]+ was observed at m/z 409.1751 (C23H25N2O5
+, -1.61 ppm), sharing 6 fragment 
ions with M2 (see Table SI1 and Figure SI13): m/z 244, 144, 116, 101, 83, and 55. Ammonia 
loss was not observed for this metabolite. Based on this information, this metabolite could be 
produced after the oxidation of the hydroxyl group present in the N-alkylic chain of M4, or 
after the oxidative deamination of M2. Thus, M5 presented two carboxylic acid moieties in 
both sides of the molecule. Finally, the fragmentation pathway of M5 was proposed, based on 
compound structure and observed fragmentation (Figure SI14). 
M6 and M7 were only observed in ESI‒, presenting low sensitivity. M6 [M‒H]‒ was detected 
at m/z 306.1250 (C18H16N3O2
‒, 4.14 ppm). As explained previously, the detection of the 
fragment at m/z 116 (indole ring) revealed that this moiety was not affected during hepatocyte 
incubation. Based on the elemental composition, the biotransformation should correspond to 
the N-dealkylation of 5F-APP-PICA. Only two fragment ions were observed (see Table SI1), 
being Fragment 1 (m/z 189.0663, C10H9N2O2
‒, 2.36 ppm) the loss of the indole ring as a neutral 
loss, and Fragment 2 the indole ring itself (m/z 116.0494, C8H6N
‒, -0.91 ppm). Figure SI15 
shows MS/MS spectra at 10 and 50 eV. The fragmentation pathway proposed can be seen in 
Figure SI16. 
M7 was the last phase I metabolite identified, which [M‒H]‒ was found at m/z 307.1089 
(C18H16N2O3
‒, 3.90 ppm). The fragment at m/z 190.0504 (C10H8NO3
‒, 3.90 ppm) (see Table 
SI1) would be equivalent to m/z 189 in M6, whereas the fragment at m/z 116 was common to 
M6. Following the same metabolic pathway than M3, M4 and M5, and based on the elemental 
composition calculated, M7 was obtained after an oxidative deamination from M6 (the terminal 
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amide moiety changed to a carboxylic acid). The other three observed fragments (Fragments 
2, 3 and 5, Table SI1) confirmed the hypothesis of the oxidative deamination from M6. Finally, 
a fragmentation pathway was proposed (Figure SI18), justifying all the fragments observed in 
MS/MS spectra at 10 and 50 eV (Figure SI17). 
Phase II metabolites 
Once identified the phase I metabolites, the phase II metabolites were searched for by 
considering different conjugations to phase I metabolites. Glucuronide, sulphate, phosphate 
and glutathione conjugates were investigated in both ionisation modes. Up to 5 glucuronides 
conjugates were detected in the DDA acquisition and thus, acquired in MS/MS in order to 
confirm the structure of the phase II metabolites (Table SI1). 
M1-Gluc and M2-Gluc were only detected in ESI‒. For M1-Gluc, only the [M‒H]‒ was 
observed, without any fragment ion, probably due to its low sensitivity or abundance. M2-Gluc 
showed 2 fragment ions: Fragment 1 at m/z 406, corresponding to the loss of the glucuronide 
(and thus, releasing the [M‒H]‒ of M2), and Fragment 2 at m/z 116, corresponding to the indole 
ring. MS/MS spectra at 10 eV for M1-Gluc, and at 10 and 50 eV for M2-Gluc for both phase 
II metabolites are shown in Figure SI19 and Figure SI20, respectively. 
M3-Gluc, M4-Gluc and M5-Gluc were detected in both ionisation modes, but presenting a 
higher sensitivity in ESI+. All the fragments ions were shared with their corresponding phase I 
metabolites (see Table SI1), being highly specific and locating the unequivocal position of the 
glucuronidation for metabolites M4 and M5 which possess two possible conjugation sites. So, 
M3, M4 and M5 presented conjugation on the carboxylic acid moiety linked to the amide 
moiety. MS/MS spectra at 10 and 50 eV corresponding to these three metabolites can be found 
in Figure SI21 (M3-Gluc), Figure SI22 (M4-Gluc) and Figure SI23 (M5-Gluc). 
3.4. AMB-FUBINACA metabolites 
Phase I metabolites 
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M1-M5 presented a common fragment at m/z 109 (C7H6F
+), also present in AMB-
FUBINACA, which corresponds to the fluorotropylium fragment ion. The presence of this 
unaltered fragment indicated that no biotransformations were expected on the fluorobenzyl 
side-chain. The absence of biotransformations on this moiety has also been described for other 
synthetic cannabinoids with an N-fluorobenzyl, such as AB-FUBINACA and ADB-
FUBINACA 25,42. 
M1 [M+H]+ was observed at m/z 370.1560 (C20H21FN3O3
+, -0.30 ppm), corresponding to a 
demethylation. The presence of a water molecule loss (m/z 352.1455, C20H19FN3O2
+, -0.30 
ppm) followed by a CO loss (m/z 324.1506, C19H19FN3O
+, -0.29 ppm) indicated an O-
demethylation in the terminal methyl ester moiety. This pathway is similar to AMB-
FUBINACA, which presented a methanol loss (fragment at m/z 352) followed by a CO loss 
(fragment at m/z 324). Other fragments at m/z 271, 253 and 109 were shared with AMB-
FUBINACA (see Table SI2). The high response of M1 allowed the detection of an additional 
fragment at m/z 72.0815 (C4H10N
+, 10.43 ppm), corresponding to the nitrogen atom bonded to 
the isopropyl moiety. After that, a plausible fragmentation pathway was proposed (Figure 
SI25) based on the MS/MS fragmentation at 10 and 30 eV (Figure SI24). 
M2, M3 and M4 were observed at m/z 386, all 3 corresponding to hydroxylations of M1 (for 
the information of their complete fragmentation, see Table SI2). The position of the 
hydroxylation point was successfully determined after an accurate fragmentation study. The 
easiest one was M4 (m/z 386.1507, C20H21FN3O4
+, -0.95 ppm), rapidly identified after the 
evaluation of their fragments at m/z 269.0719 (C15H10FN2O2
+, -0.57 ppm) and m/z 109. The 
presence of the unaltered fluorotropylium ion (Fragment 3) indicated that the hydroxylation 
was on the indazole ring. The Fragment 2 (m/z 269) would correspond to the fragment ion 4 of 
AMB-FUBINACA (m/z 253). All fragments observed in MS/MS spectra (Figure SI26) were 
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successfully justified based on the proposed structure, and the fragmentation pathway was also 
proposed (Figure SI27). 
M2 (m/z 386.1508, C20H21FN3O4
+, -0.63 ppm) and M3 (m/z 386.1513, C20H21FN3O4
+, 0.71 
ppm) structures were not so directly identified as M4. The presence of a fragment ion at m/z 
253 (shared with AMB-FUBINACA) revealed that the indazole and fluorophenyl moieties 
were not changed. Both compounds presented an initial loss of a water molecule (fragment at 
m/z 368); for M3, a second loss of water was observed (m/z 350) whereas for M2 the loss of 
water plus CO was found (fragment at m/z 322) (see Table SI2). As AMB-FUBINACA 
presented also the loss of a water molecule followed by a CO loss, it was expected that M2 and 
M3 were hydroxylated on the isopropyl moiety, explaining the second water loss observed for 
these metabolites. Nevertheless, M3 presented a characteristic fragment ion, which revealed 
the position of the hydroxyl group in this metabolite. The Fragment 3 of M3 (m/z 310.1349, 
C18H17FN3O
+, -0.52 ppm) corresponded to a CH2O + CO loss from Fragment 1. The CO loss 
was originated from the carbonyl moiety after the first water loss; the CH2O loss could only be 
explained if the hydroxyl group was in one of the methyl groups of the isopropyl moiety. This 
CH2O + CO loss was not observed for M2, and the fragmentation occurred through losses of 
water and CO molecules, indicating that the hydroxyl group should be on the tertiary carbon 
of the isopropyl group. All the fragment ions observed for M2 and M3 (see Table SI2) in the 
MS/MS spectra at 10 and 30 eV (Figure SI28 and Figure SI30, respectively) were successfully 
justified based on the proposed structure, and their fragmentation pathways could be proposed 
(Figure SI29 and Figure SI31, respectively). 
M5 (m/z 400.1674, C21H23FN3O4
+, 1.69 ppm) was produced after the hydroxylation of 
AMB-FUBINACA. On the basis of the fragmentation observed for the parent compound and 
M2-M4, the position of the hydroxyl group could be directly stablished. As a fragment ion at 
m/z 253 was observed, the hydroxylation on the indazole ring was discarded. M5 fragmentation 
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was similar to M3, keeping in mind that M3 was O-demethylated respect M5. Fragment at m/z 
350 (Fragment 2) was observed for M5 and M3, and the CH2O loss observed for M2 was not 
present. Based on these premises, M5 should have a hydroxyl on the tertiary carbon of the 
isopropyl. The proposed fragmentation pathway (Figure SI33) could justify all the observed 
fragments in MS/MS spectra at 10 and 30 eV (Figure SI32).  
M6 was observed at m/z 262.1185 (C13H16N3O3
+, -0.57 ppm), and its elemental composition 
revealed that this metabolite should be produced after an N-dealkylation from M1, as the mass 
difference respect to the parent, corresponded to a fluorobenzyl loss. Fragment 3 (m/z 
145.0396, C8H5N2O
+, -0.52 ppm) and 2 (Fragment 3+H2O, m/z 163.0501, C8H7N2O2
+, -0.48 
ppm) confirmed the N-dealkylation of this metabolite. Moreover, the consecutive losses of H2O 
and CO observed in Fragment 1 (m/z 216.1131, C12H14N3O
+, 0.02 ppm) confirmed the presence 
of a carboxylic acid moiety, as these losses were also observed for M1. Thus, all the MS/MS 
fragments (Figure SI34, Table SI2) were justified based on the proposed structure for M6, 
and the fragmentation pathway was stablished (Figure SI35). 
M7 was the last phase I metabolite identified for AMB-FUBINACA, observed at m/z 
276.1342 (C14H18N3O3
+, -0.23 ppm). Based on the elemental composition, it was expected that 
M7 was the N-dealkylation product of AMB-FUBINACA. Nevertheless, the fragmentation 
evaluation revealed that this preliminary evaluation was not the correct one. Similar to M6 and 
M1, the consecutive losses of H2O and CO (Fragment 1, m/z 230.1288, C13H16N3O
+, -0.15 
ppm) indicated the presence of a carboxylic acid moiety on the molecule. Thus, M7 should also 
correspond to an O-demethylation. The correct position of this extra methyl moiety was 
determined by Fragment 3 (m/z 159.0552, C9H7N2O
+, -0.52 ppm), locating it in the nitrogen of 
the indazole ring after an N-methylation of M6. On this way, a tentative fragmentation pathway 
(Figure SI37) was proposed for this structure, justifying all the MS/MS fragments (Figure 
SI36, Table SI2). 
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Phase II metabolites 
Only one phase II metabolite was identified in the DDA analyses in ESI+ and confirmed by 
MS/MS (Table SI2) to be the glucuronide corresponding to M1 (M1-Gluc).  
M1-Gluc presented exactly the same fragmentation than M1, including the fragment ion 
corresponding to the loss of the glucuronide, this is, to M1 (Fragment 1, m/z 370). The complete 





















































































































































Figure SI23. Proposed fragmentation pathway for AMB-FUBINACA M1 based on the 










Figure SI25. Proposed fragmentation pathway for AMB-FUBINACA M4 based on the 











Figure SI27. Proposed fragmentation pathway for AMB-FUBINACA M2 based on the 











Figure SI29. Proposed fragmentation pathway for AMB-FUBINACA M3 based on the 











Figure SI31. Proposed fragmentation pathway for AMB-FUBINACA M5 based on the 











Figure SI33. Proposed fragmentation pathway for AMB-FUBINACA M6 based on the 











Figure SI35. Proposed fragmentation pathway for AMB-FUBINACA M7 based on the 





Figure SI36. MS/MS spectra of AMB-FUBINACA M1-Gluc at 10 eV (top) and 50 eV 
(bottom) collision energy. 
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Table SI1. MS/MS fragmentation of 5F-APP-PICA and its metabolites, including 1 
retention time, ionization mode, and elemental composition, accurate mass and mass 2 
error (in ppm) for (de)protonated molecule and fragment ions. 3 
Metabolite Retention time (min) ESI [M+H]+/– (m/z) Elemental composition Mass error (ppm) Fragment ion (m/z) Elemental composition 
5F-APP-PICA 7.94 + 396.2083 C23H27FN3O2
+ 0.18 379.1815 C23H24FN2O2
+ 
            232.1132 C14H15FNO
+ 
            144.0444 C9H6NO
+ 
            69.0706 C5H9
+ 
M1 6.70 + 394.2116 C23H28N3O3
+ -2.31 377.1851 C23H25N2O3
+ 
            230.1170 C14H16NO2
+ 
            144.0441 C9H6NO
+ 
            116.0493 C8H6N
+ 
            87.0809 C5H11O
+ 
            69.0705 C5H9
+ 
M2 6.63 + 408.1908 C23H26N3O4
+ -2.42 391.1642 C23H23N2O4
+ 
            244.0963 C14H14NO3
+ 
            144.0441 C9H6NO
+ 
            116.0495 C8H6N
+ 
            101.6000 C5H9O2
+ 
            83.0496 C5H7O
+ 
            55.0550 C4H7
+ 
M3 8.32 + 397.1916 C23H26FN2O3
+ -1.61 232.1128 C14H15FNO
+ 
            144.0441 C9H6NO
+ 
            116.0494 C8H6N
+ 
            69.0705 C5H9
+ 
M4 7.07 + 395.1958 C23H27N2O4
+ -1.85 230.1171 C14H16NO2
+ 
            144.0441 C9H6NO
+ 
            87.0808 C5H11O
+ 
            69.0705 C5H9
+ 
M5 6.98 + 409.1751 C23H25N2O5
+ -1.61 244.0964 C14H14NO3
+ 
            144.0442 C9H6NO
+ 
            116.0494 C8H6N
+ 
            101.0600 C5H9O2
+ 
            83.0497 C5H7O
+ 
            55.0552 C4H7
+ 
M6 6.32 – 306.1250 C18H16N3O2
– 4.14 189.0663 C10H9N2O2
– 
            116.0494 C8H6N
– 
M7 6.74 – 307.1089 C18H15N2O3
– 3.90 190.0504 C10H8NO3
– 
            164.0708 C9H10NO2
– 
            147.0441 C9H7O2
– 
            116.0493 C8H6N
– 
            72.0077 C2H2NO2
– 
M1-Gluc 5.89 – 568.2294 C29H34N3O9
– 0.73     
M2-Gluc 5.80 – 582.2098 C29H32N3O10
– 2.78 406.1774 C23H24N3O4
– 
            116.0494 C8H6N
– 
M3-Gluc 7.24 + 357.2238 C29H34FN2O9
+ -0.93 555.2118 C29H32FN2O9
+ 
            397.1918 C23H26FN2O3
+ 




            144.0441 C9H6NO
+ 
M4-Gluc 6.19 + 571.2290 C29H35N2O10
+ 0.67 230.1172 C14H16NO2
+ 
            144.0440 C9H6NO
+ 
M5-Gluc 6.14 + 585.2079 C29H33N2O11
+ 0.00 224.0963 C14H14NO3
+ 
            144.0440 C9H6NO
+ 
            101.0601 C5H9O2
+ 
 4 
  5 
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Table SI2. MS/MS fragmentation of AMB-FUBINACA and its metabolites, including 6 
ionization mode, and elemental composition, accurate mass and mass error (in ppm) for 7 































+ -0.35 352.1455 C20H19FN3O2
+ -0.12 10 
            324.1507 C19H19FN3O
+ 0.09 30 
            271.0877 C15H12FN2O2
+ -0.09 30 
            253.0771 C15H10FN2O
+ -0.14 30 
            109.0451 C7H6F
+ 3.45 50 




+ -0.30 352.1455 C20H19FN3O2
+ -0.30 10 
            324.1506 C19H19FN3O
+ -0.29 30 
            271.0876 C15H12FN2O2
+ -0.43 30 
            253.0770 C15H10FN2O
+ -0.50 30 
            109.0452 C7H6F
+ 2.82 50 
            72.0815 C4H10N
+ 10.43 30 




+ -0.63 368.1400 C20H19FN3O3
+ -1.31 10 
            322.1344 C19H17FN3O
+ -1.82 30 
            271.0874 C15H12FN2O2
+ -1.33 30 
            253.0769 C15H10FN2O
+ -1.10 30 
            109.0451 C7H6F
+ 3.17 50 




+ 0.71 368.1409 C20H19FN3O3
+ 1.01 10 
            350.1290 C20H17FN3O2
+ -2.67 30 
            310.1349 C18H17FN3O
+ -0.52 30 
            271.0876 C15H12FN2O2
+ -0.54 30 
            253.0769 C15H10FN2O
+ -1.10 30 
            109.0453 C7H6F
+ 2.82 50 




+ -0.95 340.1459 C19H19FN3O2
+ 1.01 10 
            269.0719 C15H10FN2O2
+ -0.57 30 
            109.0451 C7H6F
+ 2.89 50 




+ 1.69 382.1555 C21H21FN3O3
+ -1.57 10 
            350.1297 C20H17FN3O2
+ -0.20 30 
            271.0875 C15H12FN2O2
+ -0.99 30 
            253.0771 C15H10FN2O
+ -0.20 30 
            109.0450 C7H6F
+ 2.89 50 




+ -0.57 216.1131 C12H14N3O
+ 0.02 10 
            163.0501 C8H7N2O2
+ -0.48 50 
            145.0396 C8H5N2O+ -0.52 50 
            72.0815 C4H10N
+ 10.22 50 




+ -0.19 230.1288 C13H16N3O
+ -0.15 10 
            177.0658 C9H9N2O2
+ -0.50 50 
            159.0552 C9H7N2O+ -0.52 50 
            72.0815 C4H10N
+ 10.22 50 




+ -0.23 528.1772 C26H27FN3O8
+ -0.80 10 
            370.1558 C20H21FN3O3
+ -0.87 10 
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            324.1503 C19H19FN3O
+ -0.10 30 
            271.0876 C15H12FN2O2
+ -0.43 50 
            253.0771 C15H10FN2O
+ -0.26 50 
            109.0452 C7H6F
+ 3.31 50 
            72.0815 C4H10N
+ 10.75 30 
 9 
 10 
 11 
